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FDG-PET has changed lymphoma management at staging
and for response assessment due to its capability to
improve disease characterization and treatment selection.
New recommendations have been made by the ICML
working group in 2014. FDG-PET is now recommended
for staging in the vast majority of lymphoma since almost
all types of lymphoma are FDG-avid. It has been shown
recently that FDG-PET due to its high sensitivity for
bone marrow involvement in Hodgkin lymphoma can
obviate the bone marrow biopsy. In addition FDG PET
may be used to target biopsy and based on the local
SUVmax to detect transformation.
For response assessment after treatment or during che-
motherapy the HIP2007 criteria have now been replaced
by the Deauville criteria using a 5-point scale. Initially pro-
posed for the evalaution of interim PET these criteria are
now extended for end treatment evaluation. The residual
activity observed after treatment is scored against different
levels of backgroung i.e: 1.no uptake, 2. uptake uptake ≤
mediastinum but ≤ liver, 3. uptake > mediastinum, 4.
uptake moderately higher than liver, 5. uptake markedly
higher than liver and/or new lesions. A score 4 has been
chosen as the threshold for positivity both at interim and
end treatment. The value of this choice has been demon-
strated in validation studies. Using these criteria FDG PET
has demonstrated its prognostic value early in the course
of the treatment or at end treatment in Hodgkin
lymphoma, Diffuse large B cell lymphoma and Follicular
Lymphoma. A tailored therapy based on interim PET is
under study in many ongoing trials but at the present time
it is not recommendend to change therapy on the basis of
the results of an interim FDG-PET. Quantitative analysis
of metabolic volume at staging or Δ SUVmax response
assessment and their prognostic values and various trends
in the future will be discussed.
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